Evaluation of Vitamin D Levels in Psoriasis Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01903317|
Recruitment Status : Withdrawn (No subjects enrolled)
First Posted : July 19, 2013
Last Update Posted : October 12, 2015
|Condition or disease||Intervention/treatment|
|Psoriasis||Other: Topical Therapy Other: Phototherapy and Systemic Therapy Other: Biologic Therapy|
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Evaluation of Vitamin D Levels in Psoriasis Patients|
|Study Start Date :||June 2013|
|Actual Primary Completion Date :||July 2015|
|Actual Study Completion Date :||July 2015|
Subjects who use topical therapy as the standard treatment of care for their psoriasis.
Other: Topical Therapy
Subjects will continue use of topical therapy (e.g. topical corticosteroids, keratolytic agents, anthralin, coal tar, vitamin D analogs, retinoids) for their psoriasis as if they were not participating in this study.
Phototherapy and Systemic Therapy
Subjects who use phototherapy and systemic therapy as the standard treatment of care for their psoriasis.
Other: Phototherapy and Systemic Therapy
Subjects will continue use of phototherapy (e.g. ultraviolet B [UVB] or ultraviolet A and psoralen [PUVA]) and systemic therapy (e.g. methotrexate, cyclosporine) for their psoriasis as if they were not participating in this study.
Subjects who use biologic therapy as the standard treatment of care for their psoriasis.
Other: Biologic Therapy
Subjects will continue use of biologic therapy (e.g. etanercept, adalimumab, ustekinumab) for their psoriasis as if they were not participating in this study.
- The relationship between level of vitamin D and psoriasis severity [ Time Frame: 52 Weeks ]Subjects will have their disease severity evaluated and a vitamin D level drawn at Baseline (prior to initiating treatment), Week 12, Week 24, and Week 52.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01903317
|United States, California|
|University of California Irvine, Dermatology|
|Irvine, California, United States, 92697|
|Principal Investigator:||Jennifer Soung, M.D.||University of California, Irvine|